Sushil Patel
Patrimonio netto: 15 M $ in data 31/08/2026
Patrimonio netto: 15 M $ in data 31/08/2026
Sushil Patel is Chief Executive Officer & Director at Replimune Group, Inc. since 2024 and an Independent Director at Revolution Medicines, Inc. since 2022.
Formerly, Dr. Patel was Vice President-Franchise & Head-Oncology at Genentech, Inc. from 2018 to 2021.
Education includes an undergraduate degree from the University of Warwick in 1992, a graduate degree from Imperial College London in 1993, and a doctorate from the University of London in 1999.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/08/2026 | 708.151 ( 0,75% ) | 11 M $ | 31/08/2026 | |
| 29/06/2026 | 21.656 ( 0,01% ) | 4 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| REPLIMUNE GROUP, INC. | Amministratore Delegato | 01/04/2024 |
| REVOLUTION MEDICINES, INC. | Direttore/Membro del Consiglio | 16/06/2022 |
| Società | Posizione | Fine |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/05/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale